Niagen Bioscience (NAGE) Shares Outstanding (Diluted Average) (2010 - 2026)

Niagen Bioscience (NAGE) has 15 years of Shares Outstanding (Diluted Average) data on file, last reported at $84.6 million in Q1 2026.

• Shares Outstanding (Diluted Average) for Q1 2026 came in at $84.6 million, up 1.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $84.6 million (up 1.6% YoY), and the FY2025 annual result was $85.4 million, up 9.36% from the prior year.
• Shares Outstanding (Diluted Average) declined to $84.6 million in Q1 2026 per NAGE's latest filing, from $85.4 million in the prior quarter.
• Over five years, Shares Outstanding (Diluted Average) peaked at $86.2 million in Q2 2025 and troughed at $68.3 million in Q1 2022.
• A 5-year average of $76.8 million and a median of $75.2 million in 2024 frame the typical range for Shares Outstanding (Diluted Average).
• The sharpest annual moves came in 2022 and 2025: Shares Outstanding (Diluted Average) increased 0.16% in 2022, then advanced 14.14% in 2025.
• A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $69.7 million in 2022, then advanced by 7.54% to $75.0 million in 2023, then gained by 4.19% to $78.1 million in 2024, then grew by 9.36% to $85.4 million in 2025, then retreated by 1.02% to $84.6 million in 2026.
• Business Quant data shows NAGE's Shares Outstanding (Diluted Average) at $84.6 million in Q1 2026, $85.4 million in Q4 2025, and $85.5 million in Q3 2025.